CIN1Cervical Intraepithelial Neoplasia 1 (abnormal cervical cell growth)
References in periodicals archive ?
With many studies of immune-based therapies missing the mark, this RCT demonstrates histopathologic regression from high-grade CIN to CIN1 or normal pathology in the DNA vaccine group
Among these women, rates of new CIN1 or worse or CIN2 or worse were higher in women with than without HIV: 7.
In 2011, new national guidelines were published with algorithms for HPV testing for the following indications: (i) triage of women with borderline cytology (atypical squamous cells of undetermined significance and atypical glandular cells), (ii) triage of women over 35 with lowgrade intraepithelial lesions, (iii) triage of women with CIN1, and (iv) prediction of outcome after treatment of [CIN.
Pap smears were reported according to the Bethesda classification, (8) which allows additional descriptors of CIN1, 2 and 3.
Their recommendation now states that follow-up after adequate colposcopy with a biopsy revealing CIN1 or HPV effect may include either repeat cervical cytology tests at 6 and 12 months or HPV testing at 12 months.
LightTouch) offers the potential of a cost effective test that provides an immediate result at the point of care while detecting significantly more moderate and high-grade dysplasia (disease) and significantly reducing the need for additional testing for benign (no disease) and CIN1 (low risk) lesions," according to one of five abstracts discussing the pivotal trial results.
Severity of cervical intraepithelial neoplasia is graded CIN1, CIN2, and CIN3.
The percentage of cases in which p16 staining was used was calculated for each pathologist and was then correlated with the age of the patients (dichotomized as younger than 30 years and 30 years or older), prior Pap test diagnosis (dichotomized as <LSIL [low-grade squamous intraepithelial lesion] and [greater than or equal to] LSIL), prior HPV test results (classified as negative, low-risk HPV, and high-risk HPV [hr-HPV]), the number of cervical biopsies interpreted by each pathologist, their frequency of biopsy diagnoses (no CIN, CIN1 and CIN2, CIN3 or squamous cell carcinoma, henceforth referred to as CIN2+), and the ratios of CIN1/CIN2+ and of CIN2+/ (CIN1 + CIN2+).
Women in the trial, which was sponsored by Photocure, had pathologically confirmed, previously untreated CIN1 or CIN2.
The paraffin blocks of biopsy material have been stained by the hematoxylin-eosin technique for histological classification, as follows: LSIL, HSIL, where LSIL category included the results with CIN1, and HSIL the findings with CIN 2 and 3 diagnoses.
On the other hand, it is recommended that the earliest lesions, CIN1, should not be treated and should be followed up and treated only if they progress to higher lesion.